Syngenta/Chemchina equity financing highlights Beijing backing; but deal not seen as ‘critical’ to China
* Deal not make or break to agri modernization policy
* Syngenta spun to lenders as a deal about food security
The level of SOE backed equity supporting the financing of ChemChina’s USD 43bn bid for Swiss crop protection and seed technology company Syngenta [VTX: SYNN] highlights its importance to Beijing. But the deal is not a make or break element of China’s stated strategy to modernize its agricultural production and achieve food security, said academics, advisors and analysts.
When China’s largest ever outbound acquisition was announced in February this year ChemChina Chairman Ren Jianxin said it would be extremely important to China and its farmers and that it would benefit the environment. Reports have repeatedly stressed how the deal fits with Beijing’s plans to modernize agriculture and reduce reliance on food imports over the next five years.
Agricultural productivity was firmly placed high on the policy agenda by President Xi Jinping in a December 2013 speech. Since then, the Number One Central Document, the 13th Five-Year-Plan and ‘Made in China 2025’ program has focused on agriculture modernization.
A source briefed on the deal said the acquisition of Syngenta was pitched to financing banks as a deal about food security. It is a deal that will improve agricultural yield and help feed a billion people, the source said. China has arable land of around 100m hectares which on a per capita basis, sits in the world’s lowest quantile, according to Singapore Management University PhD student Henry Chan.
The fact that equity to fund the deal has only been made available to SOE investors signals Beijing is the main force behind the deal, the source added.
Three-fifths of the 25% equity component backing the deal will come from the Ministry of Finance and the state-owned Assets Supervision and Administration Commission (SASAC), the source said. The balance of the equity component will come from external government-linked investors such as the Silk Road Fund, the source added.
Aside from the amount of equity provided by SOEs, the major criteria to measure the government’s support for the deal include the cost of loans from state banks and how much support the Chinese government provides to drive ChemChina’s operational turnaround, said Jiming Zou, Moody's vice president and senior analyst.
Evidence of the government’s interest in the deal came in April when a spokesperson for the Ministry of Commerce said the proposed acquisition of Syngenta is a normal and straightforward M&A transaction that does not pose a security risk to US food supply. Such comments are relatively rare and it was seen as a direct message to the Committee on Foreign Investment in the United States’ (CFIUS).
In accordance with the tender offer, ChemChina is required to take all action and to supply all information necessary to obtain regulatory approvals for its tender offer unless such actions would result in the reduction of the consolidated sales of one year of USD 2.68bn or more. Or in the case of CFIUS, remove all oversight, management and control of ChemChina to businesses, assets or operations of Syngenta which contributed to consolidated sales of Syngenta of USD 1.54bn or more in the financial year 2015.
Important but not seen as critical
A former China affairs advisor to the US government said the Syngenta deal will facilitate or link China’s broader strategic policy efforts. But while it would be a big win for China if the acquisition closes, it is not a make-or-break deal for the country, the advisor said.
Chan agreed the deal will contribute to China’s efforts to modernize its agriculture activity but said it is not critical for the country in the short term. For instance, China’s approach to improving seed quality is to use hybridization rather than genetically modified organisms, which is a key aspect of what Syngenta brings, he said.
Acquiring Syngenta’s GMO technologies would enhance China’s reserve of technological assets, to help address challenges in the next decade or so, said Professor Yang Jun of the University of International Business and Economics (UIBE). These benefits would not come immediately and would not be obvious but it is a strategic long-term move, he added.
China is experiencing a widening gap between the supply and demand of various crops, such as the oversupply of corn and scarcity of soybean, drawing the need for imports, Rabobank analyst Chenjun Pan said.
Yet the deal will not bring instant relief to China’s concerns about food security, a research fellow at the Chinese Academy of Agricultural Sciences (CAAS) said. The near-term benefits would be owning crop protection technologies that help lift crop yield, while the seed genetics business could improve technological capabilities in seed in the long run, he added.
The government is adjusting its view on its currently limited use of GMO technology, a China-based agriculture analyst and the CAAS research fellow said, adding it is a matter of time before the PRC lifts controls on transgenic technology. Syngenta has the best transgenic and breeding technologies, the analyst added. Yang added that Syngenta will expand China’s portfolio of soybean and corn GMO technologies, enabling the country to grow its own GMO crops in the future.
In the past year China has increasingly signalled it would relax its opposition to GMOs. Earlier this month China released its latest five-year plan for science and technology, saying it would push for the commercialisation of biotech corn and soybeans in the next few years.
China’s about-face on GMOs came in late 2014 when a pro GMO ad campaign from the agriculture ministry reportedly began. Interestingly this came just months before ChemChina made its initial expression of interest to Syngenta on 8 May 2015. That was the same day the Swiss company first acknowledged it had rejected a CHF 449 cash/share offer from Monsanto.
For ChemChina, the Syngenta acquisition came at a cost-effective time as the Swiss target is facing operational pressure, said Yang. Whether or not the deal bears fruit for China depends how well ChemChina integrates Syngenta’s businesses post-deal, Yang added.
When asked if the sale to ChemChina was a policy-driven transaction, a spokesperson for Syngenta said it has no bearing on the deal and that this was simply a change of ownership. Syngenta management will continue to run the company and its headquarters will remain in Switzerland, the spokesperson added.
This deal does benefit all stakeholders, the Syngenta spokesperson added, as ChemChina recognizes the quality and potential of Syngenta's manufacturing and R&D.
Shares in Syngenta are trading at 24.1% spread to CHF 475 offer price (excluding dividend).